John Newman
Stock Analyst at Canaccord Genuity
(2.17)
# 2,944
Out of 5,099 analysts
89
Total ratings
43.59%
Success rate
-3.81%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Maintains: Buy | $130 | $70.33 | +84.84% | 10 | Dec 8, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 → $1,057 | $715.93 | +47.64% | 20 | Dec 4, 2025 | |
| CMPX Compass Therapeutics | Initiates: Buy | $10 | $5.26 | +90.29% | 1 | Dec 3, 2025 | |
| NUVL Nuvalent | Initiates: Buy | $126 | $103.84 | +21.34% | 1 | Nov 12, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $9.72 | +116.05% | 2 | Oct 21, 2025 | |
| MRUS Merus | Downgrades: Hold | $67 → $97 | $96.79 | +0.22% | 3 | Sep 30, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $16.75 | +31.34% | 10 | Sep 24, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.46 | +858.90% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $94.99 | +80.48% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $16.98 | +0.12% | 5 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.43 | +460.62% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $25 | $5.71 | +337.83% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.55 | +1,354.02% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $7.70 | +458.44% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.98 | +412.14% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $27.62 | +59.30% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $13.73 | +176.77% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $4.75 | +469.02% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $15.62 | - | 1 | Sep 13, 2017 |
Arcellx
Dec 8, 2025
Maintains: Buy
Price Target: $130
Current: $70.33
Upside: +84.84%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $715.93
Upside: +47.64%
Compass Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $5.26
Upside: +90.29%
Nuvalent
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $103.84
Upside: +21.34%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $9.72
Upside: +116.05%
Merus
Sep 30, 2025
Downgrades: Hold
Price Target: $67 → $97
Current: $96.79
Upside: +0.22%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $16.75
Upside: +31.34%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.46
Upside: +858.90%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $94.99
Upside: +80.48%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $16.98
Upside: +0.12%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.43
Upside: +460.62%
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.71
Upside: +337.83%
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.55
Upside: +1,354.02%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $7.70
Upside: +458.44%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.98
Upside: +412.14%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $27.62
Upside: +59.30%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $13.73
Upside: +176.77%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $4.75
Upside: +469.02%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $15.62
Upside: -